Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2Phase NA 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Genitourinary 2Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1Plasma cell 1Myeloid 1

Conditions

Uveal Melanoma 1Melanoma 1Carcinoma, Merkel Cell 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19HhAntag691 19Mycophenolic Acid 18Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × oblimersen × Dermatologic × Clear all
NCT01200342 2016-02-11

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

M.D. Anderson Cancer Center

Phase 2 Terminated
7 enrolled 3 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT00079131 2013-06-04

Oblimersen in Treating Patients With Merkel Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡